In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Commentary|Podcasts|March 10, 2026
Pharma Pulse: Ipsen’s Global Tazemetostat Withdrawal and FDA Approval of Deucravacitinib for Psoriatic Arthritis
Author(s)Stephen Appezzato
In today's Pharma Pulse, Ipsen voluntarily withdraws tazemetostat due to safety signals, while the FDA approves deucravacitinib for active psoriatic arthritis.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.
- Ipsen is
voluntarily withdrawing tazemetostat (Tazverik) from all markets effectively immediately. This global withdrawal follows safety signals in the confirmatory SYMPHONY-1 trial, which identified concerning patterns of secondary hematologic malignancies. Ipsen is now working closely with the FDA to formally execute the withdrawal and support patient transitions to alternative treatments. - In other news, the FDA has
approved Bristol Myers Squibb's Sotyktu , also known as deucravacitinib, for adults with active psoriatic arthritis. As the first and only TYK2 oral pill for this condition, Sotyktu demonstrated superiority over placebo in Phase 3 trials, significantly improving both joint pain and skin clearance.
That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
3
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5